JP7575944B2 - 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 - Google Patents

構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 Download PDF

Info

Publication number
JP7575944B2
JP7575944B2 JP2020532689A JP2020532689A JP7575944B2 JP 7575944 B2 JP7575944 B2 JP 7575944B2 JP 2020532689 A JP2020532689 A JP 2020532689A JP 2020532689 A JP2020532689 A JP 2020532689A JP 7575944 B2 JP7575944 B2 JP 7575944B2
Authority
JP
Japan
Prior art keywords
bfl
peptide
noxa
seq
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506800A5 (enExample
JP2021506800A (ja
Inventor
ローレン ディー． ワレンスキー，
グレゴリー エイチ． バード，
レイチェル グェルラ，
エドワード ハービー，
Original Assignee
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド filed Critical デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド
Publication of JP2021506800A publication Critical patent/JP2021506800A/ja
Publication of JP2021506800A5 publication Critical patent/JP2021506800A5/ja
Priority to JP2023120833A priority Critical patent/JP2023129587A/ja
Application granted granted Critical
Publication of JP7575944B2 publication Critical patent/JP7575944B2/ja
Priority to JP2026019183A priority patent/JP2026086637A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020532689A 2017-12-15 2018-12-13 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 Active JP7575944B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023120833A JP2023129587A (ja) 2017-12-15 2023-07-25 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化
JP2026019183A JP2026086637A (ja) 2017-12-15 2026-02-09 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599229P 2017-12-15 2017-12-15
US62/599,229 2017-12-15
PCT/US2018/065438 WO2019118719A1 (en) 2017-12-15 2018-12-13 Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023120833A Division JP2023129587A (ja) 2017-12-15 2023-07-25 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化

Publications (3)

Publication Number Publication Date
JP2021506800A JP2021506800A (ja) 2021-02-22
JP2021506800A5 JP2021506800A5 (enExample) 2022-02-28
JP7575944B2 true JP7575944B2 (ja) 2024-10-30

Family

ID=65276261

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020532689A Active JP7575944B2 (ja) 2017-12-15 2018-12-13 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化
JP2023120833A Pending JP2023129587A (ja) 2017-12-15 2023-07-25 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化
JP2026019183A Pending JP2026086637A (ja) 2017-12-15 2026-02-09 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023120833A Pending JP2023129587A (ja) 2017-12-15 2023-07-25 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化
JP2026019183A Pending JP2026086637A (ja) 2017-12-15 2026-02-09 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化

Country Status (6)

Country Link
US (3) US11834520B2 (enExample)
EP (1) EP3737404A1 (enExample)
JP (3) JP7575944B2 (enExample)
AU (1) AU2018383633B2 (enExample)
CA (1) CA3079758A1 (enExample)
WO (1) WO2019118719A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｆｌ－１と結合するペプチド
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides
WO2025155817A1 (en) * 2024-01-17 2025-07-24 Regents Of The University Of Minnesota Lymphocytes including altered noxa activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040329A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
WO2017040323A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
US20040093164A1 (en) 2002-11-08 2004-05-13 Carlson William D. Computer system and methods for producing morphogen analogs of human TDF-1
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1718748A1 (en) 2004-02-06 2006-11-08 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules and methods for generating and/or selecting same
EP1910535B1 (en) 2005-06-24 2016-08-17 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2013102211A2 (en) 2011-12-29 2013-07-04 Walensky Loren D Stabilized antiviral fusion helices
BR112014016744A2 (en) 2012-01-06 2018-09-04 Complix Nv polypeptide, pharmaceutical composition and method for producing one or more polypeptides
WO2013116829A1 (en) 2012-02-03 2013-08-08 The Trustees Of Princeton University Novel engineered potent cytotoxic stapled bh3 peptides
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2019118719A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040329A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
WO2017040323A2 (en) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein

Also Published As

Publication number Publication date
US11834520B2 (en) 2023-12-05
CA3079758A1 (en) 2019-06-20
JP2023129587A (ja) 2023-09-14
US20240132544A1 (en) 2024-04-25
AU2018383633B2 (en) 2024-05-16
JP2026086637A (ja) 2026-05-26
US20210070802A1 (en) 2021-03-11
US12466853B2 (en) 2025-11-11
AU2018383633A1 (en) 2020-04-23
WO2019118719A1 (en) 2019-06-20
US20240228539A9 (en) 2024-07-11
US20260226104A1 (en) 2026-08-06
EP3737404A1 (en) 2020-11-18
JP2021506800A (ja) 2021-02-22

Similar Documents

Publication Publication Date Title
US20240140999A1 (en) Stabilized peptide-mediated targeted protein degradation
US12570698B2 (en) Stabilized peptides for covalent binding to target protein
US12466853B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
JP7394903B2 (ja) Ｂｆｌ－１と結合するペプチド
US10308926B2 (en) Stablized EZH2 peptides
US20240075099A1 (en) COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
HK40126659A (en) Stabilized peptide-mediated targeted protein degradation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241018

R150 Certificate of patent or registration of utility model

Ref document number: 7575944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150